Finn's Take· TL;DRLenacapavir is widely seen as a game-changing tool for eradicating HIV, offering virtually complete protection against contracting the virus with just one administration every six months. Now, the people who need it most may finally be able to get it. On Monday, November 2, the U.S. Food and Drug Administration gave tentative approval to a generic version of the drug — and the price tag tells the whole story: Dr. Reddy's lenacapavir injection will be available at $40 per person per year for the 120 low- and middle-income countries included in Gilead's voluntary license. That's compared to over $28,000 per year for the brand-name version in the United States.
Lenacapavir was first developed by U.S. pharmaceutical company Gilead Sciences and approved in June 2025 after proving more than 99.9% effective in large clinical trials. The generic approval comes just 16 months after the FDA approved Gilead Sciences' originator lenacapavir for HIV prevention. That's a remarkably compressed timeline for a generic drug — a sign of how urgently global health advocates pushed to get this medicine into the hands of vulnerable populations.
In late 2024, Gilead granted voluntary licenses for lenacapavir to six generic manufacturers. Even before generic availability, more than 125,000 people in 10 early adopter African countries had already started Gilead's lenacapavir. Those licensing deals — royalty-free and non-exclusive — were designed specifically to accelerate access in resource-limited settings.
The generic was granted "tentative approval" by the FDA under an accelerated pathway that allows sponsors to use existing data. Approval of a drug by the U.S. FDA can speed regulatory approval in many other countries, meaning this decision carries weight well beyond American borders. Dr. Reddy's Laboratories, one of the world's largest generic drugmakers, plans to start shipping the medicine next month as part of an effort propelled, in part, by several global health organizations.
The global HIV burden remains staggering. An estimated 1.2 million people acquired HIV last year, even as a medicine offering near-100% protection with just two injections a year now exists. An estimated 41 million people worldwide are currently living with HIV, and roughly 570,000 died from HIV-related causes last year. The gap between what science can do and what the world's poorest patients can access has never been more glaring — or more fixable.
For people at risk of HIV infection, this means a long-acting injectable prevention option that doesn't require a daily pill, at a price in line with oral PrEP — a key condition for uptake in low- and middle-income countries. Daily oral PrEP requires consistent adherence, which is difficult in settings with limited healthcare infrastructure. Two injections a year is a fundamentally different ask. Lenacapavir was named "Breakthrough of the Year" in 2024 by the prestigious journal Science, which hailed the basic research underpinning the drug, specifically a new understanding of HIV's capsid protein.
Experts are celebrating the approval while being clear-eyed about what comes next. "Generic lenacapavir has the potential to transform HIV prevention, and this is a significant milestone, but an affordable drug alone is not enough," said Professor Saiqa Mullick, Director of Implementation Science at Wits RHI, University of the Witwatersrand. Funding, logistics, and political will all remain obstacles — particularly as global aid budgets face pressure. UNAIDS estimates that the permanent discontinuation of HIV prevention and treatment programs supported by PEPFAR would lead to an additional 6.6 million new HIV infections between 2025 and 2029.
Initial supplies of the generic are expected to reach countries by the end of 2026. The deals do exclude some middle-income countries like Brazil, where the HIV burden remains high — a gap that advocates say must be addressed. Still, with a proven drug, a workable price, and regulatory momentum building, the world has something it hasn't had before in the fight against HIV: a realistic path to near-elimination of new infections, if the will and the funding follow the science.